Upadacitinib

When it Comes to Treating Ulcerative Colitis, US Gastroenterologists May be Betting it All on JAK…

Retrieved on:

星期四, 十一月 30, 2023

Marketing, IBD, Failure, Adalimumab, Risankizumab, MOA, Gastroenterology, Physician, Ustekinumab, HCP, Ulcerative colitis, Injection, UC, RealTime, JAK, Patient, Celltrion, Upadacitinib, Pharmaceutical industry

Over the past two months, the landscape of UC treatment has undergone a significant expansion, introducing four new options.

Key Points:

Over the past two months, the landscape of UC treatment has undergone a significant expansion, introducing four new options.
The first line of UC treatment remains overwhelmingly dominated by the firmly established anti-TNF therapies (such as Humira and Remicade) alongside Entyvio.
Furthermore, the favored choice among physicians in Crohn’s disease (CD), Stelara, has continued to enjoy a position in later-line UC treatment.
Patient Chart Dynamix™ is an independent, data-driven service unveiling real patient management patterns through rigorous analysis of large-scale patient chart audits.

Eli Lilly's Olumiant and Pfizer's Litfulo Strengthen Alopecia Areata Arsenal, Yet Resounding Opportunity for JAK Expansion and New Assets in Development Remain

Retrieved on:

星期三, 十一月 15, 2023

Despite this, Olumiant is anticipated to maintain a substantial lead over Litfulo in the market.

Key Points:

Despite this, Olumiant is anticipated to maintain a substantial lead over Litfulo in the market.
Prescribers of both brands express high and comparable satisfaction levels, far surpassing the satisfaction rates associated with non-advanced systemic treatment options.
Recent data from Spherix's published studies highlight minimal differentiation among prescribers regarding the two JAK inhibitors.
Furthermore, barriers preventing increased use of either JAK inhibitor remain closely contested, with safety concerns topping the list for each asset.

US Gastroenterologist Projections Suggest Significant Shift in Ulcerative Colitis Landscape Afoot, with Launches of Eli Lilly's Omvoh, Pfizer's Velsipity, Takeda's Subcutaneous Entyvio, and Celltrion's Zymfentra

Retrieved on:

星期一, 十一月 13, 2023

These additions come amidst an already bustling market, teeming with both branded and increasingly competitive biosimilar alternatives.

Key Points:

These additions come amidst an already bustling market, teeming with both branded and increasingly competitive biosimilar alternatives.
However, the influx of innovative agents suggests that upcoming changes are poised to be more substantial and transformative.
This extension enjoys the highest pre-launch familiarity and generates significantly higher interest in gaining approval.
Although prescribers display significant enthusiasm for Entyvio SC, its anticipated impact on the broader market is projected to be modest.

Lupus Therapeutics Partners with AbbVie on Clinical Trial Recruitment Efforts in SLE Through LuCIN Lupus Clinical Trial Network

Retrieved on:

星期二, 十月 24, 2023

SLE, Lupus Research Alliance, Inflammation, Lupus, Tablet, Partnership, Autoimmune disease, AbbVie, Safety, Upadacitinib, Therapy, Pharmaceutical industry

NEW YORK, Oct. 24, 2023 /PRNewswire/ -- Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, announces a partnership with AbbVie Inc. for the Phase 3 clinical program of upadacitinib (RINVOQ®) in individuals living with systemic lupus erythematosus (SLE).

Key Points:

NEW YORK, Oct. 24, 2023 /PRNewswire/ -- Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, announces a partnership with AbbVie Inc. for the Phase 3 clinical program of upadacitinib (RINVOQ®) in individuals living with systemic lupus erythematosus (SLE).
In this partnership, Lupus Therapeutics will assist with study participant recruitment, site activation and engagement efforts through the Lupus Clinical Investigators Network (LuCIN) of top academic centers throughout North America.
Lupus Therapeutics announces a partnership with AbbVie Inc. for the Phase 3 program of upadacitinib (RINVOQ®) in lupus.
Lupus Therapeutics and the Lupus Research Alliance are committed to accelerating the development of potential treatments for a community in urgent need of more options.

Odyssey Therapeutics Appoints Jeremy Sokolove, MD as Chief Medical Officer

Retrieved on:

星期三, 十月 4, 2023

Odyssey Therapeutics, Inc. , a biotechnology company pioneering next-generation precision immunomodulators and oncology medicines, today announced the appointment of Jeremy Sokolove, M.D., as chief medical officer.

Key Points:

Odyssey Therapeutics, Inc. , a biotechnology company pioneering next-generation precision immunomodulators and oncology medicines, today announced the appointment of Jeremy Sokolove, M.D., as chief medical officer.
In this role, Dr. Sokolove will develop, lead and drive the development strategy and execution of all Odyssey’s clinical assets.
View the full release here: https://www.businesswire.com/news/home/20231004996667/en/
Jeremy Sokolove, M.D., Chief Medical Officer of Odyssey Therapeutics, Inc. (Photo: Business Wire)
“As the newest member of our executive leadership team, Dr. Sokolove’s medical expertise and background in the biopharmaceutical industry will be critical to the success of our clinical development programs and achieving our corporate goals,” said Gary D. Glick, Ph.D., founder and CEO of Odyssey Therapeutics.
“It’s an exciting time to join Odyssey as the organization transitions to a clinical-stage biotechnology company,” said Dr. Sokolove.

Consecutive Use of TNF-Inhibitors for the Treatment of Psoriatic Arthritis at Lowest Point Recorded, as Use of Biologics with Alternate Mechanisms of Actions Continue to Grow, According to Spherix Global Insights

Retrieved on:

星期二, 十月 3, 2023

This results in a substantial patient population, with each physician handling an average of forty or more patients who switch their treatment on an annual basis.

Key Points:

This results in a substantial patient population, with each physician handling an average of forty or more patients who switch their treatment on an annual basis.
Spherix Global Insights recently published its seventh annual Patient Chart Dynamix™: Triggers and Drivers in Psoriatic Arthritis, (previously RealWorld Dynamix: Switching in Psoriatic Arthritis).
Patients receiving TNFs are also provided an ample period of treatment in the first-line setting before considering a switch to an alternative therapy.
Patient Chart Dynamix™ is an independent, data-driven service unveiling real patient management patterns through rigorous analysis of large-scale patient chart audits.

Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors

Retrieved on:

星期二, 六月 20, 2023

REDWOOD CITY, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of Scott Brun, M.D., to Jasper’s Board of Directors. Dr. Brun will also join Jasper’s Research and Development Committee as Chairperson and become a member of Jasper’s Compensation Committee. Concurrently, board member Vishal Kapoor has been appointed to join Jasper’s Audit and Compensation Committees. Additionally, Lawrence Klein, Ph.D., has stepped down from Jasper’s Board of Directors as of June 20, 2023, due to requirements of his recent appointment as a Partner of Versant Ventures.

Key Points:

Dr. Brun will also join Jasper’s Research and Development Committee as Chairperson and become a member of Jasper’s Compensation Committee.
Concurrently, board member Vishal Kapoor has been appointed to join Jasper’s Audit and Compensation Committees.
Additionally, Lawrence Klein, Ph.D., has stepped down from Jasper’s Board of Directors as of June 20, 2023, due to requirements of his recent appointment as a Partner of Versant Ventures.
He was most recently a Senior Advisor to Horizon Therapeutics and Vice President of Scientific Affairs and Head of AbbVie Ventures.

Ulcerative Colitis Treatment Market to Grow Exponentially by 2029- Brandessence Market Research

Retrieved on:

星期四, 五月 18, 2023

The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.

Key Points:

The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.
It examines various treatment options available for ulcerative colitis, including medications, surgery, and other therapies.
High Cost of Treatment: One of the major challenges in the ulcerative colitis treatment market is the high cost associated with the available treatment options.
FMT is being explored as a potential treatment option for ulcerative colitis, with ongoing clinical trials assessing its safety and efficacy.

Ulcerative Colitis Treatment Market to Grow Exponentially by 2029- Brandessence Market Research

Retrieved on:

星期四, 五月 18, 2023

The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.

Key Points:

The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.
It examines various treatment options available for ulcerative colitis, including medications, surgery, and other therapies.
High Cost of Treatment: One of the major challenges in the ulcerative colitis treatment market is the high cost associated with the available treatment options.
FMT is being explored as a potential treatment option for ulcerative colitis, with ongoing clinical trials assessing its safety and efficacy.

Approximately One-Year Post-Launch, AbbVie's Rinvoq Boasts Increasingly Favorable Perceptions Among Gastroenterologists for the Treatment of Ulcerative Colitis, According to Spherix Global Insights

Retrieved on:

星期三, 五月 17, 2023

EXTON, Pa., May 17, 2023 /PRNewswire/ -- In March of 2022, the FDA approved AbbVie's JAK1 inhibitor, Rinvoq (upadacitinib), for the treatment of moderate to severe ulcerative colitis (UC).

Key Points:

EXTON, Pa., May 17, 2023 /PRNewswire/ -- In March of 2022, the FDA approved AbbVie's JAK1 inhibitor, Rinvoq (upadacitinib), for the treatment of moderate to severe ulcerative colitis (UC).
According to Spherix's most recent RealTime Dynamix: Ulcerative Colitis (US) Q2 update, the majority of gastroenterologists are highly satisfied with the brand.
In fact, when pinned head-to-head against other leading UC brands on key agent attributes, Rinvoq has also made strong perceptual gains.
Spherix will continue to track the overall UC and CD markets and pulse gastroenterologists on their perceptions and intentions to use advanced therapies in their RealTime Dynamix services.